Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.

The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results.  ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Latest News

Antisense Therapeutics appoints new Non-Executive Director

Positive feedback received on Paediatric Investigation Plan

Statistically significant modulation in two DMD disease modifier proteins supports potential of ATL1102 in ambulant DMD and fibrotic conditions

New ATL1102 proteomics data to be presented in a Late Breaking News Abstract at the World Muscle Society 2021 Virtual Congress

World Duchenne Day – 7 September 2021

ANP to participate in US-based Jett Foundation’s World Duchenne Awareness Day Celebrations

ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA

ANP Updates on US Regulatory Plans for ATL1102 in DMD

Antisense Therapeutics transitions to new Board Chair

Antisense Therapeutics and Murdoch Children’s Research Institute enter into new R&D collaboration to further explore ATL1102 use in multiple muscle diseases. 

Menu